Vident Investment Advisory, LLC Sage Therapeutics, Inc. Transaction History

Vident Investment Advisory, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$40.26 - $57.37 $150,773 - $214,850	-3,745 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$54.88 - $79.29 $205,525 - $296,941	3,745 New	3,745 $213,000
Q1 2020 May 12, 2020	SELL	$26.15 - $77.24 $105,410 - $311,354	-4,031 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$60.18 - $154.77 $6,379 - $16,405	-106 Reduced 2.56%	4,031 $291,000
Q3 2019 Nov 13, 2019	BUY	$140.29 - $189.96 $4,910 - $6,648	35 Added 0.85%	4,137 $580,000

Q2 2019 Aug 12, 2019	BUY	$157.85 - $183.09 $46,881 - $54,377	297 Added 7.81%	4,102 $751,000
Q1 2019 May 08, 2019	BUY	$89.33 - $163.65 $16,347 - $29,947	183 Added 5.05%	3,805 $605,000
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $18,846 - $32,133	-230 Reduced 5.97%	3,622 $347,000
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $534,761 - $654,522	-3,872 Reduced 50.13%	3,852 $544,000
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $134,885 - $168,905	961 Added 14.21%	7,724 $1.21 Million
Q1 2018 May 14, 2018	BUY	$152.15 - $192.33 $1.03 Million - $1.3 Million	6,763 New	6,763 $1.1 Million

220

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $730M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.